Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Maravai LifeSciences HoldingsMRVI +2.36%62 3-Year ROIIC % is 60.16 as of Dec. 2025, which is 3% above its 10-year median of 58.45. GuruFocus rates MRVI with a GF Score™ of 62/100 and a GF Value™ of $3.82 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,322 Biotechnology companies, Maravai LifeSciences Holdings ranks better than 73.22% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Maravai LifeSciences Holdings's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 60.16%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Maravai LifeSciences Holdings 3-Year ROIIC % Related Terms
Maravai LifeSciences Holdings 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MRVI vs LBRX, SLDB, JANX: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Maravai LifeSciences Holdings's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maravai LifeSciences Holdings 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Maravai LifeSciences Holdings's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Maravai LifeSciences Holdings's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Maravai LifeSciences Holdings (MRVI) has a 3-Year ROIIC % of 60.16 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Maravai LifeSciences Holdings and its competitors. This is near median its historical median of 58.45. Over the past decade, Maravai LifeSciences Holdings' 3-Year ROIIC % has ranged from 45.86 to 85.03. According to the industry distribution chart, Maravai LifeSciences Holdings ranks #354 out of 1322 companies in the Biotechnology industry, placing it in the top 26.8%.
Is Maravai LifeSciences Holdings' 3-Year ROIIC % too high?
Maravai LifeSciences Holdings' current 3-Year ROIIC % of 60.16 is near median its 10-year median of 58.45. Over the past 10 years, this metric has ranged from a low of 45.86 to a high of 85.03. Based on the distribution chart, Maravai LifeSciences Holdings ranks #354 out of 1322 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Maravai LifeSciences Holdings has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Maravai LifeSciences Holdings' 3-Year ROIIC % compare to LBRX and SLDB?
According to the Biotechnology industry distribution chart, Maravai LifeSciences Holdings ranks #354 out of 1322 companies for 3-Year ROIIC %. This puts Maravai LifeSciences Holdings in the upper half of its industry. Historically, Maravai LifeSciences Holdings' own 3-Year ROIIC % has ranged from 45.86 to 85.03 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Maravai LifeSciences Holdings and its competitors. Maravai LifeSciences Holdings's current 3-Year ROIIC % is 60.16, which is near median its own 10-year median of 58.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maravai LifeSciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Maravai LifeSciences Holdings (MRVI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.82, compared to a current price of $6.51 — trading 70.4% above its estimated fair value. The current 3-Year ROIIC % is 60.16, which is near median its 10-year median of 58.45. Maravai LifeSciences Holdings' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Maravai LifeSciences Holdings (MRVI), the current 3-Year ROIIC % is 60.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maravai LifeSciences Holdings (MRVI) Overvalued in 2026?
Based on GuruFocus' analysis, Maravai LifeSciences Holdings stock appears to be overvalued.
The current stock price of $6.51 is trading 70.4% above its estimated GF Value™ of $3.82.
GuruFocus considers Maravai LifeSciences Holdings to be Significantly Overvalued.
Key valuation signals for MRVI:
3-Year ROIIC %: 60.16 (near median its 10-year median of 58.45)
GF Value™: $3.82 vs. price of $6.51 (70.4% above fair value)
No single metric tells the full story. See the MRVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maravai LifeSciences Holdings Business Description
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
62GF Score
Get the complete analysis for MRVI
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MRVI has been successfully added to your 
